[FLASH SALE] Global Induced Pluripotent Stem Cell (iPSC) Industry Report – Market Size, Trends, & Forecasts, 2026

Description

Published June 2026
Market Report; 317 Pages

Just released: This week only, you can claim this global strategic report for an unusual 20% off.

Since the discovery of induced pluripotent stem cell (iPSC) technology in 2006, significant progress has been made in stem cell biology and regenerative medicine. New pathological mechanisms have been identified and explained, new drugs identified by iPSC screens are in the pipeline, and the first clinical trials employing human iPSC-derived cell types have been initiated. iPSCs are being used to explore the causes of disease onset and progression, create and test new drugs and therapies, and treat previously incurable diseases.

Today, methods of commercializing induced pluripotent stem cells (iPSCs) include:

• Cellular Therapy: iPSCs are being explored in a diverse range of cell therapy applications for the purpose of reversing injury or disease.
• Disease Modelling: By generating iPSCs from patients with disorders of interest and differentiating them into disease-specific cells, iPSCs can effectively create disease models “in a dish”.
• Drug Development and Discovery:iPSCs have the potential to transform drug discovery by providing physiologically relevant cells for compound identification, target validation, compound screening, and tool discovery.
• Personalized Medicine: The use of techniques such as CRISPR enable precise, directed creation of knock-outs and knock-ins (including single base changes) in many cell types. Pairing iPSCs with genome editing technologies is adding a new dimension to personalized medicine.
• Toxicology Testing: iPSCs can be used for toxicology screening, which is the use of iPSCs or their derivatives (tissue-specific cells) to assess the safety of compounds or drugs within living cells.
• Tissue Engineering: iPSCs can be seeded onto scaffolds made from biocompatible materials. These scaffolds mimic the structure and properties of the target tissue and can provide a supportive environment for cell growth and differentiation.
• Organoid Production: iPS cells can be coaxed to self-organize into 3D structures called organoids, which mimic the structure and function of organs. Organoids can be used for studying organ development, modeling diseases, and testing drugs.
• Gene Editing: iPS cells can be genetically modified using techniques like CRISPR-Cas9 to correct disease-causing mutations or introduce specific genetic changes. These edited iPS cells can then be differentiated into the desired cell type for transplantation or disease modeling.
• Research Tools: iPSCs and iPSC-derived cell types are being widely used within a diverse range of basic and applied research applications.
• Stem Cell Banking: iPSC repositories provide researchers with the opportunity to investigate a diverse range of conditions using iPSC-derived cell types produced from both healthy and diseased donors.
• Cultured Meat Production: iPSCs are being utilized in clean meat production by serving as the cellular foundation for the creation of lab-grown meat.
• 3D Bioprinting: iPSCs can be directed to differentiate into cell types of interest, such as skin, heart, or liver cells, which are then incorporated into bioinks.
• Wildlife Conservation and De-extinction Projects: iPSCs are being used in wildlife conservation and de-extinction projects. For example, Colossal Biosciences is using iPSC technology in an effort to achieve woolly mammoth de-extinction.

iPSC Market Dynamics

Since the discovery of iPSCs in 2006, it took only seven years for the first iPSC-derived cell product to be transplanted into a human patient in 2013. Since then, iPSC-derived cells have been used within a rapidly growing number of preclinical studies, physician-led studies, and clinical trials worldwide.

The discovery of iPSC has not only favorably transformed the field of drug discovery, toxicity testing and in-a-dish disease modeling, but also powerfully impacted the field of cell and gene therapy. The ability of iPSCs to multiply in vitro and then get differentiated into specialized cells makes iPSCs an ideal source of cells of different types for curative clinical cell replacement therapies and disease modeling.

Of course, 2013 was a landmark year because it saw the first cellular therapy involving the transplant of iPSCs into humans initiated at the RIKEN Center in Kobe, Japan. Led by Dr. Masayo Takahashi, it investigated the safety of iPSC-derived cell sheets in patients with macular degeneration. In another world first, Cynata Therapeutics received approval in 2016 to launch the first formal clinical trial of an allogeneic iPSC-derived cell product (CYP-001) for the treatment of GvHD. CYP-001 is an iPSC-derived MSC product. In this historic trial, CYP-001 met its clinical endpoints and produced positive safety and efficacy data for the treatment of steroid-resistant acute GvHD.

Today, at least 155 ongoing clinical trials are using iPSC-derived specialized cells to address various indications. iPSC-derived MSCs are being tested in the treatment of steroid-resistant acute graft versus host disease (GvHD). iPSC-derived dopaminergic progenitors are being evaluated in the treatment of Parkinson’s disease. iNK cell-based cancer immunotherapy is being studied in the treatment of metastatic solid tumors. iPSC-derived retinal pigment epithelial cells have shown positive results in the treatment of age-related macular degeneration (AMD). Furthermore, iPSC derived insulin secreting beta cells are being tested for the treatment of Type 1 diabetes.

Although iPSCs have the potential to be used in both allogeneic and autologous applications, the development of allogeneic therapies using iPSC-derived products is outpacing the development of autologous therapies. Several allogeneic therapies utilizing iPSC-derived cells derived from healthy donors are being used to address diabetes, Parkinson’s disease, and AMD, and these therapies are now progressing through clinical trials in human patients.

Market competitors are also commercializing iPSC-derived products for use in drug development and discovery, disease modeling, and toxicology testing. Across the broader iPSC sector, FUJIFILM CDI (FCDI) is one of the largest and most dominant players. Cellular Dynamics International (CDI) was founded in 2004 by Dr. James Thomson at the University of Wisconsin-Madison, who in 2007 derived iPSC lines from human somatic cells for the first time. The feat was accomplished simultaneously by Dr. Shinya Yamanaka’s lab in Japan. FUJIFILM acquired CDI in April 2015 for $307 million. Today, the combined company (FCDI) is the world’s largest manufacturer of human cells created from iPSCs for use in research, drug discovery and regenerative medicine applications.

Another iPSC specialist is ReproCELL, a company that was established as a venture company originating from the University of Tokyo and Kyoto University in 2009. It became the first company worldwide to make iPSC products commercially available when it launched its ReproCardio product, which are human iPSC-derived cardiomyocytes.

Within the European market, the dominant competitors are Evotec, Ncardia, and Axol Bioscience. Headquartered in Hamburg, Germany, Evotec is a drug discovery alliance and development partnership company. It is developing an iPSC platform with the goal to industrialize iPSC-based drug screening as it relates to throughput, reproducibility, and robustness. Today, Evotec’s infrastructure represents one of the largest and most advanced iPSC platforms globally.

Ncardia was formed through the merger of Axiogenesis and Pluriomics in 2017. Its predecessor, Axiogenesis, was founded in 2011 with an initial focus on mouse embryonic stem cell-derived cells and assays. When Yamanaka’s iPSC technology became available, Axiogenesis became the first European company to license it in 2010. Today, the combined company (Ncardia) is a global authority in cardiac and neural applications of human iPSCs. Founded in 2012, Axol Bioscience is a smaller but noteworthy competitor that specializes in iPSC-derived products. Headquartered in Cambridge, UK, it specializes in human cell culture, providing iPSC-derived cells and iPSC-specific cell culture products.

Of course, the world’s largest research supply companies are also commercializing a diverse range of iPSC-derived products and services. Examples of these companies include Lonza, BD Biosciences, Thermo Fisher Scientific, Merck, Takara Bio, and countless others.  In total, at least 90 market competitors now offer a diverse range of iPSC products, services, technologies, and therapeutics.

iPSC-Derived Cellular Therapeutics

In other historic news, at least 72 global competitors are now forging the path toward iPSC-derived cell therapeutics. This is astounding market growth given that iPSCs were discovered less than 20 years ago.

These market leaders include:

• Allele Biotech is developing a diabetes drug created from iPSC-derived pancreatic beta cells.
• Aspen Neuroscience is developing the world’s first autologous iPSC-derived neuron replacement therapy for Parkinson’s disease.
• Avery Therapeutics and I Peace, Inc., are collaborating to advance an iPSC-derived cell therapeutic for heart failure.
• Bayer acquired iPSC cell therapy company BlueRock Therapeutics in August 2019 to develop iPSC-derived therapies for ocular diseases, Parkinson’s disease, and heart failure.
• BeiGene is pursuing iPSC-derived cell therapies focused on enhancing the potency of γδ and αβ T-cells for cancer treatment.
• BlueRock Therapeutics develops iPSC-derived cell therapies for Parkinson’s disease, heart failure, and ocular diseases.
• Bone Therapeutics has partnered with Implant Therapeutics to develop allogeneic iPSC-derived MSCs.
• Brooklyn Immuno Therapeutics is developing iPSC-derived MSC products with gene editing technology for immune therapy.
• Cartherics is creating genetically engineered iNK cells from iPSCs to target cancer.
• CellOrigin Biotech (Hangzhou) Co, Ltd is developing allogeneic iPSC-derived CAR macrophages to treat cancer.
• Cellectis is partnering with Cytovia Therapeutics to produce gene-edited iNK cells derived from iPSCs.
• Cellistic is producing iPSC-derived CAR-NKT cells for cancer therapy.
• Century Therapeutics develops iPSC-derived immune effector cell therapies for cancer and immune disorders.
• Citius Pharmaceuticals uses iPSCs to create MSCs for allogeneic therapies, including in diabetes.
• Clade Therapeutics is developing immune-cloaked iPSC-derived cell therapies for various diseases.
• Cuorips Inc. is developing cardiac tissue sheets from iPSCs to treat coronary artery disease.
• Creative Medical Technology Holdings, Inc. is developing iPSC-derived insulin-producing Islet Cells for diabetes treatment.
• Cynata Therapeutics manufactures iPSC-derived MSCs for treating GvHD, osteoarthritis, and respiratory failure.
• CytoMed Therapeutics develops iPSC-derived gamma delta natural killer T cells for cancer immunotherapy.
• Cytovia Therapeutics is developing gene-edited, allogeneic iNK and CAR-iNK cells derived from iPSCs.
• Edigene, Inc. and Neukio Biotherapeutics are co-developing allogeneic iPSC-derived NK cells for cancer therapy.
• Editas Medicine is developing iPSC-derived natural killer cells for cancer treatment.
• Eterna Therapeutics is developing gene-edited iPSCs for immune responses and hematopoietic regeneration.
• Exacis Biotherapeutics is developing iPSC-derived NK cells using mRNA gene-editing for cancer treatment.
• Fate Therapeutics is developing iPSC-derived NK and CAR-T cells for cancer and immune disorders.
• FUJIFILM Cellular Dynamics, Inc. supports iPSC-derived cell therapy development through its production facility.
• GC Therapeutics (GCTx) uses its TFome platform to develop iPSC-based therapies for neurological and immune diseases.
• Gameto is developing iPSC-derived solutions to mature eggs for IVF and egg freezing.
• Go Liver Therapeutics is developing iPSC-derived liver therapies for regenerative medicine.
• Greenstone Bio is using AI and patient-derived iPSCs to accelerate drug discovery.
• Heartseed Inc. is developing iPSC-derived cardiomyocytes for treating heart failure.
• Healios K.K. is conducting clinical trials using iPSC-derived retinal cells to treat macular degeneration.
• Hebecell is commercializing allogeneic iPSC-derived NK cell therapies for cancer treatment.
• Hopstem Biotechnology is developing iPSC-derived therapies for ocular diseases in partnership with Neurophth Biotechnology.
• Implant Therapeutics is developing hypo-immunogenic iPSC-derived MSCs for ex-vivo gene therapy.
• IN8bio is reprogramming donor cells into iPSCs to differentiate into gamma-delta T cells for cancer immunotherapy.
• I Peace Inc. and Avery Therapeutics are advancing an iPSC-derived heart failure therapy.
• Ipsell is using iPSCs for cell line production and disease modeling to develop stem cell-based treatments.
• IPS HEART is developing iPSC-derived heart muscle for treating heart disease, including Duchenne Cardiomyopathy.
• iPSirius SAS is developing a cancer vaccine leveraging iPSCs and cancer stem cell similarities.
• iRegene Therapeutics is developing iPSC-derived treatments for Parkinson’s and retinal diseases using AI and chemical induction.
• Jacobio Pharmaceuticals is partnering with Hebecell to develop iPSC-derived NK cells for cancer treatment.
• Kenai Therapeutics is developing iPSC-derived dopamine progenitor cells for Parkinson’s disease.
• Keio University is conducting a trial using iPSC-derived therapies for spinal cord injuries.
• Kiji Therapeutics is developing engineered iPSC-derived MSCs for various therapeutic applications.
• Kyoto University Hospital is conducting a trial using iPSC-derived dopaminergic progenitors for Parkinson’s disease.
• Laverock Therapeutics is developing iPSC-derived cell therapies with improved efficacy through gene editing.
• Mytos‘ iDEM platform replaces traditional iPSC manufacturing with a closed, automated system that delivers consistent, GMP-ready cells
• Neurophth Biotechnology Ltd. is developing iPSC-derived therapies for retinal diseases in collaboration with Hopstem Biotechnology.
• Notch Therapeutics is developing iPSC-derived T-cells for hematological malignancies in partnership with Allogene Therapeutics.
• Novo Nordisk is co-developing iPSC-derived heart failure therapies with Heartseed.
• Osaka University developed iPS-derived corneal cell sheets for patients with limbal stem cell deficiency.
• Pluristyx and panCELLa merged to create genetically modified, “off-the-shelf” iPSCs for cell therapy.
• REPROCELL offers a “Personal iPS service” to store individual iPSCs for future medical use.
• RIKEN pioneered the world’s first iPSC-derived therapeutic cell transplant for AMD in 2014.
• RheinCell Therapeutics GmbH manufactures GMP-compliant iPSCs from HLA-homozygous umbilical cord blood.
• RxCell Inc. develops universal iPSC lines for allogeneic therapies, including retinal disorders.
• Ryne Biotechnology, Inc. is developing iPSC-derived dopamine neurons for Parkinson’s disease therapy.
• Sana Biotechnology is developing hypoimmune-modified iPSCs to avoid immune rejection in allogeneic therapies.
• SCG Cell Therapy Pte Ltd is using iPSC technology to expand its NK cell therapy portfolio.
• SCM Lifescience has licensed iPSC-based diabetic cell therapies developed by Allele Biotechnology.
• Semma Therapeutics, acquired by Vertex Pharmaceuticals, is developing iPSC-derived pancreatic cells for Type 1 diabetes.
• Shinobi Therapeutics is developing hypo-immune iPSC-derived T cells for cancer therapy using immune evasion.
• Shoreline Biosciences is developing allogeneic iPSC-derived NK and macrophage therapies for cancer and other diseases.
• StemSight is developing iPSC-based therapies for corneal blindness.
• Stemson Therapeutics is developing a therapy to create de novo hair follicles for hair loss treatment.
• Thyas Co. Ltd. is developing iPS-T and iPS-NK cell therapies for cancer treatment.
• Tolerance Bio is developing an iPSC-based thymus cell therapy platform for immune diseases.
• TreeFrog Therapeutics is developing iPSC-derived therapies and supports co-development through its manufacturing platform.
• The U.S. NIH is conducting the first U.S. clinical trial of an iPSC-derived therapeutic for advanced-stage geographic atrophy of the eye.
• VCCT Inc. is developing ex vivo and in vivo cell therapy solutions for ocular diseases using iPSCs.
• Vision Care Group is focused on iPSC-derived therapeutics for retinal diseases.
• Vita Therapeutics, a Cambrian Biopharma affiliate, is developing genetically engineered iPSC-derived treatments for muscular dystrophy.

Global iPSC Report

This global strategic report reveals all major market competitors worldwide, including their core technologies, strategic partnerships, and products under development. It covers the current status of iPSC research, biomedical applications, manufacturing technologies, patents, and funding events, as well as all known trials for the development of iPSC-derived cell therapeutics worldwide.

Importantly, it profiles leading market competitors worldwide and presents a comprehensive market size breakdown for iPSCs by Application, Technology, Cell Type, and Geography (North America, Europe, Asia/Pacific, and Rest of World).

It also presents total market size figures with projected growth rates through 2034.

This 317-page global strategic report will position you to:

• Capitalize on emerging trends
• Improve internal decision-making
• Reduce company risk
• Approach outside partners and investors
• Outcompete your competition
• Implement an informed and advantageous business strategy

Additional companies and organizations mentioned in the report include:

• A*STAR
• AcceGen
• Acellta, Ltd.
• AddGene, Inc.
• Allele Biotechnology, Inc.
• Almiral
• ALSTEM, Inc.
• Altos Labs
• AMS Biotechnology, Ltd. (AMSBIO)
• Applied Stem Cell (ASC)
• Asgard Therapeutics
• Aspen Neurosciences, Inc.
• Astellas Pharma, Inc.
• Atara Biotherapeutics
• Axol Biosciences, Ltd.
• Bayer AG
• BioBridge Global
• Biocentriq
• Bioqube Ventures
• bit.bio
• BlueRock Therapeutics LP
• Boehringer Ingelheim
• Bone Therapeutics
• BrainXell
• Bristol Myers Squibb
• Cartherics Pty, Ltd.
• Catalent Biologics
• CCRM
• Cellatoz
• Cellectis
• Cellino Biotech, Inc.
• Cellistic
• CellOrigin Biotech (Hangzhou) Co. Ltd.
• Cellular Engineering Technologies (CET)
• Cellusion, Inc.
• Celogics, Inc.
• Censo Biotechnologies
• Century Therapeutics, Inc.
• Charles River Laboratories
• CIRM
• Citius Pharmaceuticals, Inc.
• Clade Therapeutics
• Creative Bioarray
• Curi Bio
• Cynata Therapeutics, Ltd.
• CytoLynx
• Cytomed
• Cytovia Therapeutics
• DefiniGEN
• Edigene
• Editas Medicine
• Editco Bio. Inc.
• ElevateBio
• Elixirgen Scientific, Inc.
• Eterna Therapeutics
• Evotec
• Evotech
• Exacis Biotherapeutics
• Eyestem
• Fate Therapeutics
• FUJIFILM Cellular Dynamics, Inc.
• Fujifilm Corporation
• Gameto
• GeneCure
• Greenstone Biosciences
• Heartseed, Inc.
• Heartworks, Inc.
• Hebecell Corporation
• Helios K.K.
• Hera BioLabs
• Hopstem Biotechnology
• I Peace, Inc.
• Implant Therapeutics, Inc.
• IN8bio
• IPS HEART
• iPS Portal, Inc.
• iPSirius
• iXCells Biotechnologies
• Jacobio
• Kenai Therapeutics, Inc.
• Khloris Biosciences, Inc.
• KIF1A.ORG
• Kite
• Kytopen
• Laverock Therapeutics
• Lindville Bio, Ltd.
• Lonza Group, Ltd.
• Matricelf
• MDimmune
• Medical Center Hamburg-Eppdorf (UKE)
• Megakaryon Corporation
• Metrion Biosciences, Ltd.
• Mogrify Ltd.
• MRC Laboratory of Molecular Biology
• National Cancer Institute
• National Eye Institute
• National Resilience, Inc.
• Ncardia
• NeuCyte
• Neukio Biotherapeutics
• Neuropath Therapeutics
• Newcells Biotech
• NEXEL, Co. Ltd.
• Notch Therapeutics
• OmniaBio, Inc.
• Opsis Therapeutics
• Orizuru Therapeutics, Inc.
• Panasonic
• Pancella
• Pheno Vista Biosciences
• Phenocell SAS
• Pluristyx, Inc.
• Qihan Biotech
• Quell Therapeutics
• Ramot
• ReNeuron
• Repairon GmbH
• REPROCELL, Inc.
• Res Nova Bio, Inc.
• Resolution Therapeutics
• RheinCell Therapeutics
• Rigenerand
• Ryne Biotech
• Sana Biotechnology
• Sartorius CellGenix GmbH
• SCG Cell Therapy Pte
• Seaver Autism Center for Research and Treatment
• Sernova
• Shinobi Therapeutics
• Shoreline Biosciences
• Stemina Biomarker Discovery
• StemSight
• Stemson Therapeutics
• Synthego
• Takeda
• Tempo Bioscience, Inc.
• TEXCELL
• Thyas, Co. Ltd
• TreeFrog Therapeutics
• Uncommon (Higher Steaks)
• Undisclosed Biotech
• Universal Cells
• University of Texas
• VCCT, Inc.
• ViaCyte, Inc.
• Vita Therapeutics
• XCell Science
• Yashraj Biotechnology, Ltd.
• YiPSCELL
• And many more

With the competitive nature of this global market, you don’t have the time to do the research. Claim this report to become immediately informed, without sacrificing hours of unnecessary research or missing critical opportunities.

About BioInformant

With an online readership of nearly one million viewers per year, BioInformant is a U.S. market research firm with over 19 years of experience. As the first and only market research firm to specialize in the stem cell industry, BioInformant research has been cited by the Wall Street Journal, Xconomy, and Vogue Magazine. Founded in 2006 and headquartered in Washington, DC, BioInformant is strategically positioned to be near the National Institutes of Health (NIH), the U.S. FDA, the Maryland Biotech Corridor, and policy makers on Capitol Hill. In addition to leveraging an experienced team of analysts, BioInformant has unparalleled access to key opinion leaders (KOLs) from across the stem cell sector.

To create this report, BioInformant’s  analysts interviewed hundreds of highly regarded iPSC industry leaders. These KOLs include Kaz Hirao (President & COO of FUJIFILM CDI), Ross Macdonald (previous CEO of Cynata Therapeutics and current Chief Commercial Officer of StemSight), Dr. Nianwei Lin (Co-Founder and President of iXCells Biotechnologies), Paul Wotton (Board Member of Cynata Therapeutics), Dr. Ruby Yanru Chen-Tsai (CEO of Applied StemCell), Yutaka Yamaguchi (President of FUJIFILM Irvine Scientific), and many others, which can be viewed here.

You can review Client Reviews here.

VIEW TABLE OF CONTENTS: Global Induced Pluripotent Stem Cell (iPS Cell) Industry Report – Market Size, Trends, & Forecasts, 2026

The content within this report was compiled using a diverse range of sources, as described in this Research Methodology. View License Descriptions here.

Checkout below to get immediate access to this report, with printing rights allowed. Have questions? Email us at [email protected] to get a fast reply.